Medicare Enrolled

Dr. Malaygiri Aparnath, MD

Pulmonary Disease · Fountain Valley, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
18255 BROOKHURST ST STE 100, Fountain Valley, CA 92708
7146988028
In practice since 2007 (18 years)
NPI: 1497937460 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Aparnath from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aparnath? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Aparnath

Dr. Malaygiri Aparnath is a pulmonary disease specialist in Fountain Valley, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Aparnath performed 1,934 Medicare services across 791 unique beneficiaries.

Between the years covered by Open Payments, Dr. Aparnath received a total of $14,395 from 45 pharmaceutical and/or device companies across 620 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Aparnath is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 20% volume in CA $14,395 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,934
Medicare services
Top 20% in CA for pulmonary disease
791
Unique beneficiaries
$122
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~107 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
826 $99 $165
Critical care, first 30-74 min
Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient.
708 $176 $375
Additional 30 minutes of critical care
This code represents an additional 30 minutes of critical care services provided beyond the initial critical care time period.
101 $88 $190
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
65 $107 $303
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
58 $145 $305
Spirometry test before and after medication
A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication.
23 $35 $175
Lung volume measurement test
A test that measures the largest amount of air you can breathe in and out. It evaluates the total capacity of your lungs.
23 $13 $59
Exercise-induced lung stress test
A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising.
23 $29 $165
Inhalation treatment for airway obstruction or sputum production
A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production.
23 $8 $35
Lung volume test using sensors
A test that measures the amount of air in the lungs using sensors.
23 $50 $76
Pulmonary gas exchange test
A test to examine how well the lungs exchange gases.
23 $52 $76
Albuterol inhalation solution, 1 mg
A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation.
23 $0 $25
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
15 $66 $150
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$14,395
Total received (2018-2024)
Avg $2,056/year across 7 years
Top 12% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
620
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,141 (98.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$255 (1.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,384
2023
$3,388
2022
$2,951
2021
$2,199
2020
$1,071
2019
$1,386
2018
$17

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$563
AstraZeneca Pharmaceuticals LP
$499
Regeneron Healthcare Solutions, Inc.
$431
GENZYME CORPORATION
$320
Mylan Specialty L.P.
$273
Pulmonx Corporation
$210
Boehringer Ingelheim Pharmaceuticals, Inc.
$200
Amgen Inc.
$173
Takeda Pharmaceuticals U.S.A., Inc.
$111
SANOFI-AVENTIS U.S. LLC
$95
United Therapeutics Corporation
$95
Grifols USA, LLC
$89
Merck Sharp & Dohme LLC
$84
Vifor Pharma, Inc.
$75
Gilead Sciences, Inc.
$74
Inari Medical, Inc.
$29
Phadia US Inc.
$24
Insmed, Inc.
$21
ABBVIE INC.
$17
Top 3 companies account for 44.1% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$2,527
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,139
AstraZeneca Pharmaceuticals LP
$1,996
Regeneron Healthcare Solutions, Inc.
$1,479
Mylan Specialty L.P.
$934
GENZYME CORPORATION
$635
Ivoclar Vivadent, Inc.
$547
United Therapeutics Corporation
$538
Amgen Inc.
$500
Grifols USA, LLC
$410
Actelion Pharmaceuticals US, Inc.
$314
Takeda Pharmaceuticals U.S.A., Inc.
$258
Pulmonx Corporation
$224
PFIZER INC.
$181
SANOFI-AVENTIS U.S. LLC
$162
Philips Electronics North America Corporation
$153
Gilead Sciences, Inc.
$150
E.R. Squibb & Sons, L.L.C.
$140
Insmed, Inc.
$105
Merck Sharp & Dohme LLC
$84
Baxter Healthcare
$81
Inari Medical, Inc.
$81
Vifor Pharma, Inc.
$75
Sunovion Pharmaceuticals Inc.
$69
Resmed Corp
$64
Intuitive Surgical, Inc.
$57
AbbVie Inc.
$54
Electromed, Inc.
$48
Nabriva Therapeutics, plc
$43
Inogen, Inc.
$35
Regeneron Pharmaceuticals, Inc.
$29
PORTOLA PHARMACEUTICALS, INC.
$28
Harmony Biosciences LLC
$27
Allergan, Inc.
$26
Janssen Pharmaceuticals, Inc
$25
Phadia US Inc.
$24
Olympus America Inc.
$23
Fisher & Paykel Healthcare Inc
$21
Merck Sharp & Dohme Corporation
$19
Itamar Medical Inc
$19
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$17
ABBVIE INC.
$17
Advanced Respiratory, Inc
$14
Circassia Pharmaceuticals Inc
$12
bioMerieux
$11
Top 3 companies account for 46.3% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · 120V · 60Hz · AIRSUPRA · ALLODERM · ANDEXXA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Arikayce · Astral · BEVESPI AEROSPHERE · BREZTRI · BROVANA · CHANTIX · CHARTIS CATHETER · CUVITRU · DUPIXENT · Da Vinci Surgical System · ELIQUIS · FARXIGA · FASENRA · FISHER & PAYKEL HEALTHCARE · FLOWTRIEVER CATHETER · GLASSIA · HYQVIA · Hillrom - Life 2000 Ventilation System · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ImmunoCAP · InogenOne · Life 2000 Ventilation System · LifeVest · NUCALA · OFEV · OPSUMIT · ORENITRAM · Perforomist · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · S · SEEBRI NEOHALER · SMARTVEST · SPIRIVA RESPIMAT · SPiN Thoracic Navigation System · STIOLTO RESPIMAT · SYMBICORT · TAGRISSO · TAVNEOS · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · UPTRAVI · UTIBRON NEOHALER · VIDAS BRAHMS PCT · Veklury · WAKIX · WINREVAIR · WatchPAT · XARELTO · Xenleta · YUPELRI · Yupelri · ZERBAXA · Zemaira
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a pulmonary disease specialist in Fountain Valley?
Compare pulmonary diseases in the Fountain Valley area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
147
Per 100K population
4.6
County median income
$113,702
Nearest hospital
UCI HEALTH - FOUNTAIN VALLEY
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Aparnath is a mixed practice specialist, with above-average Medicare volume (top 20% in CA), with low-engagement industry engagement in the top 12% of CA peers, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Aparnath experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Aparnath performed 826 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Aparnath receive payments from pharmaceutical companies?
Yes. Dr. Aparnath received a total of $14,395 from 45 companies across 620 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aparnath's costs compare to other pulmonary diseases in Fountain Valley?
Dr. Aparnath's average Medicare payment per service is $122. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aparnath) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →